Nissan Chemical Industries Limited

Sakuya Tanaka

Ryozo Sakoda

Kiyotomo Seto

Keizo Tanikawa

Hiroo Matsumoto

Ken-ichi Shikada

Yoshimasa Kamikawaji

Ryozo Saloda

Kenichi Shikada

A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is hydrogen, 2-propenyl, or straight chained or branched C.sub.1 -C.sub.4 alkyl; each of R.sub.2 and R.sub.3 which may be the same or different, is hydrogen, or straight chained or branched C.sub.1 -C.sub.3 alkyl; X is chlorine, or bromine; Y is hydrogen, halogen, nitro, amino, or --AR.sub.4 wherein A is oxygen, or sulfur, and R.sub.4 is hydroen, straight chained, branched or cyclic C.sub.1 -C.sub.8 alkyl, ##STR2## wherein R.sub.5 is hydrogen, or straight chained or branched C.sub.1 -C.sub.4 alkyl; and Ar is ##STR3## wherein each Z.sub.1 and Z.sub.2 which may be the same or different, is hydrogen, halogen, straight or branched C.sub.1 -C.sub.4 alkyl, or --OR.sub.6 wherein R.sub.6 is straight or branched C.sub.1 -C.sub.4 alkyl, and B is oxygen, sulfur, or --N.dbd.C-- (to form a quinoline or pyridine ring); or a pharamaceutically acceptable salt thereof.

3(2H)pyridazinones for antagonistic agent against srs-a

A 3(2H)pyridazinone of the formula: ##STR1## wherein R.sub.1 is hydrogen, 2-propenyl or straight chained or branched C.sub.1 -C.sub.4 alkyl; R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl; X is chlorine or bromine; Y is hydrogen, nitro, -NHR.sub.3 wherein R.sub.3 is hydrogen or straight chained or branched C.sub.1 -C.sub.4 alkyl, -AR.sub.4 wherein A is oxygen or sulfur and R.sub.4 is hydrogen, straight chained or branched C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl having one double bond, C.sub.3 -C.sub.6 alkynyl having one triple bond, phenyl or ##STR2## wherein R.sub.5 is hydrogen or C.sub.1 -C.sub.4 alkyl, or halogen; Z.sub.1 is hydrogen, C.sub.1 -C.sub.4 alkyl, -OR.sub.6 wherein R.sub.6 is hydrogen, straight chained or branched C.sub.1 -C.sub.8 alkyl or ##STR3## wherein n is an integer of from 1 to 4, -N(R.sub.7).sub.2 wherein R.sub.7 is C.sub.1 -C.sub.4 alkyl, or halogen; Z.sub.2 is C.sub.1 -C.sub.4 alkyl, -OR.sub.6 wherein R.sub.6 is as defined above, -N(R.sub.7).sub.2 wherein R.sub.7 is as defined above, or halogen, provided that when R.sub.1 is straight chained or branched C.sub.2 -C.sub.4 alkyl, Y is not hydrogen and when R.sub.1 is hydrogen, methyl or 2-propenyl, Y and R.sub.2 are not simultaneously hydrogen, or a pharmaceutically acceptable salt thereof.

3(2H)pyridazinone, and antagonistic agent against SRS-A containing it

A compound of the formula: ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 which may be the same or different, is hydrogen or C.sub.1 -C.sub.4 alkyl; one of X.sup.1 and X.sup.2 is nitro, fluroine, chlorine, difluoromethyoxy or trifluoromethyl and the other is hydrogen, or both of X.sup.1 and X.sup.2 are chlorine; and Y is ##STR2## wherein A is C.sub. -C.sub.6 alkylene, each of Ar.sup.1 and Ar.sup.2 which may be the same or different, is phenyl which may be substituted by chlorine, fluorine or C.sub.1 -C.sub.3 alkoxy, and m is an integer of from 0 to 4, or Y is ##STR3## wherein A, Ar.sup.1 and Ar.sup.2 are as defined above when that both X.sup.1 and X.sup.2 are chlorine; or a pharmaceutically acceptable salt thereof.

Dihydropyridine-5-phosphonic acid cyclic propylene ester

An optical isomer of a compound having the formula: ##STR1## wherein the two methyl groups at 4- and 6-positions of the dioxaphosphorinane ring assume trans configurations to each other, which has a levo-rotatory angle of optical rotation attributable to the asymmetric carbon atom at 4-position of the dihydropyridine ring, and a pharmaceutically acceptable salt thereof.

Dihydropyridine-5-phosphonic acid cyclic ester

A compound of the formula: ##STR1## where X is hydrogen, nitro, trifluoromethyl, fluorine, chlorine, bromine or iodine; A is 1,3-propylene or 1,4-butylene which may be substituted by C.sub.1 -C.sub.3 alkyl, R is C.sub.1 -C.sub.4 alkyl, --Y--N(R.sup.1)(R.sup.2) or ##STR2## where each of R.sup.1, R.sup.2 and R.sup.3, which may be the same or different are hydrogen, C.sub.1 -C.sub.6 alkyl, or aralkyl, and Y is C.sub.2 -C.sub.6 alkylene, and Me is methyl, or its pharmaceutically acceptable salt. These compounds have utility as anti-hypertensive agents and coronary or peripheral vasodilators.

Growing community of inventors

Shiraoka, Japan

Sakuya Tanaka